Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Three patients died in Novartis trials of its CD19-directed CAR-T treatment following a dangerous immune system response, and a similar therapy from Bristol Myers Squibb